Formulation development and evaluation studies of methotrexate, nevirapine, sutezolid, levofloxacin, and ruxolitnib
Ended Awarded Last action
- Contract number
- HHSN27200002
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $57,242
Award facts
- Contract value 100% obligated
- $57,241.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$65,112 | |
| Original award | $122,354 |
Quick answers
Who was awarded contract HHSN27200002?
HHSN27200002 was awarded to Sri International by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 12, 2014.
How much is contract HHSN27200002 worth?
The government has obligated $57,242 on HHSN27200002.
Is contract HHSN27200002 an order under another contract?
Yes. HHSN27200002 is a delivery order under HHSN272201400006I, an indefinite delivery contract.
Was contract HHSN27200002 competed?
The extent of competition for HHSN27200002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award